Lipoproteins in Diabetes Mellitus

ISBN-13: 9783031266805 / Angielski

Alicia J. Jenkins; Peter P. Toth

Opis

Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. With an estimated 80% of people with diabetes living in disadvantaged regions, and the key roles of lipoproteins in the pathogenesis of the chronic complications of diabetes, this volume will be relevant to many readers globally. It is our intention that the contents will advance knowledge of the readers who will use it to contribute to the reduction of the burden associated with altered lipoproteins in people with diabetes. 
The second edition of this book provides an updated and comprehensive review of the field. The book, which includes many tables and figures, is presented in three main sections: (i) Lipoprotein metabolism, qualitative changes and measurements; (ii) Lipoproteins and the complications of diabetes; and (iii) the treatment of lipoproteins in diabetes. Each chapter from the first edition has been updated, and new topics added. New topics include the links between glycemia and lipoproteins, the role of lipoproteins in ischemic stroke, the diagnosis and management of statin intolerance (which is thought to be more common in people with diabetes) and the use of PCSK9 inhibitors and fish oils in the management of lipoproteins in people with diabetes.  This book is written by an international group of experts in the clinical, laboratory and research aspects of lipoproteins in diabetes. Lipoproteins in Diabetes Mellitus, 2nd Edition is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It is a must-have resource for primary care and specialist clinicians, clinical and basic science researchers and to trainees and students.

Spis treści

1.       Laboratory Assessment of Lipoproteins in Diabetes

David R. Sullivan and Barry Lewis

2.       Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus

Richard L Klein / Andrea Semler

3.       Links between glucose and lipoproteins

TBC 

4.       Insulin Resistance and Atherosclerosis

Kamalpreet Singh and Vasudevan A. Raghavan

5.       Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes.

Thomas D. Dayspring

6.       Lipoprotein Metabolism and Alterations Induced by Insulin Resistance and Diabetes.

Gerald H. Tomkin and Daphne Owens

7.       The PPAR System in Diabetes

Jean Claude Ansquer and Christelle Foucher

8.       Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States

Angela Pirillo, Giuseppe D. Norata, and Alberico L. Catapano

9.       Triglyceride rich lipoproteins

Bjorn G. Nordestgaard

10.    HDL function in diabetes

Anton Kontush

11.   Lipoprotein(a): Structure, Metabolism, and Pathophysiology.

Karam M. Kastner, and Gerhard M. Kostner

12.   Lipoprotein Glycation in Diabetes Mellitus.

Alicia J. Jenkins, Richard L. Klein, Andrea Semler and Andrzej S. Januszewski

13.   Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus

Marielle Kaplan, Michael Aviram, and Tony Hayek

14.   Lipid: Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes

Narin Osman and Peter J. Little

 

Lipoproteins and the Complications of Diabetes

 

15.   The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes.

Maria F. Lopes-Virella and Gabriel Virella

16.   Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy

Sandra J. Hamilton and Gerald F. Watts

17.   17. Lipoproteins and Diabetic Nephropathy. 

Ville- Petteri Makinen, Nina Tolo nen, and Per-Henrik Groop

18.   18. Lipoproteins and clinical diabetic retinopathy

TBC

19.   19   Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy

Mingyuan Wu and Timothy J. Lyon

20.   Lipoproteins and ischemic stroke in diabetes 

TBC

 

Lipoprotein Treatment in Diabetes

 

21.   About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus

Anthony Keech, Alicia J. Jenkins, and Val Gebski

22.   22. Effects of Lifestyle (Diet, Plant Sterols, Exercise) and Glycemic Control on Lipoproteins in Diabetes.

Peter Clifton

23.   Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients

Seth S. Martin, Parag H. Josh i, and Steven R. Jones

24.  Statin intolerance diagnosis and management

Maciej Banach (U of Lodz)

25.   Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients

Eliot A. Brinton

26.  EPA (fish oils) for hypertriglyceridemia in diabetes

Sephy Philip

27.   Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCI) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus

Harold Bays

28.  PSK9 inhibitors and diabetes

Peter P. Toth

29.  Lipid drug treatment in Type 1 diabetes

Alicia Jenkins, David O’Neal, Emma Scott, Jordan Fulcher

30.  Adjunct drug treatment to reduce vascular disease in diabetes

TBC

31.   Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes.

Peter J. Lillie, Alan Chait, Andrzej S. Januszewski, Alex Bobik, David O' Neal, and Alicia J. Jenkins

O autorze

Alicia J. Jenkins, MBBS, MD, FRACP, FRCP  

NHMRC Clinical Trials Centre, University of Sydney

Medical Foundation Building Level 6

92-94 Parramatta Rd

Camperdown, Sydney, 2050, NSW, Australia

alicia.jenkins@sydney.edu.au

 

Peter P. Toth, MD, PhD, FCCP, FESC, FAHA, FACC

Department of Medicine, Division of Cardiology

Johns Hopkins University School of Medicine

Baltimore, Maryland

USA

Peter.toth@cghmc.com

Alicia J. Jenkins, MBBS, MD, FRACP, FRCP is an endocrinologist and researcher. She is a Professor of Diabetes and Vascular Medicine at the University of Sydney, Australia and has honorary academic appointments at Universities in the USA, UK and Hong Kong. Her higher research degree and ongoing clinical and research relates to lipoproteins in diabetes, (clinical, biochemical and molecular) biomarkers, and to the prediction and prevention of the complications of diabetes.  She and her research team and collaborators undertake clinical and basic research and clinical trials related to diabetes and its complications and to cardiovascular disease.  She is a Chief Investigator on several investigator initiated clinical trials in diabetes, including several related to lipid drugs.  She has over 400 publications, cited over 10,000 times and an H-index of 53.  Alicia has previously worked with Peter Toth to edit the first edition of Lipoproteins in Diabetes Mellitus. Alicia works clinically in Type 1 diabetes clinics and is currently on the International Diabetes Federation Western Pacific Region Executive Council, co-Director of the Australian Cardiovascular Alliance Precision Medicine Flagship, the Lipid Guidelines Committee for the Australian Diabetes Society and President of the diabetes aid organisation Insulin For Life. 

Peter P. Toth, MD, PhD is director of preventive cardiology at the CGH Medical Center in Sterling, Illinois. He is Professor of Clinical Family and Community Medicine at the University of Illinois School of Medicine, Professor of Clinical Medicine at Michigan State University College of Osteopathic Medicine, and Adjunct Associate Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine. Dr. Toth is a past president of the National Lipid Association and American Board of Clinical Lipidology. He is President of the American Society of Preventive Cardiology. Dr. Toth has authored and coauthored over 500 publications in medical and scientific journals and textbooks. He is Series Editor of Springer’s textbook collection in Contemporary Cardiology. He has edited and written 19 textbooks on various aspects of cardiovascular medicine. He has lectured on many topics in cardiovascular medicine throughout the world. His Google Scholar score include 13,125 citations, h-index 58, and i10-index 224.